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•	 Perioperative 
 versus Preoperative 
Chemotherapy with 
Surgery in Patients with 
Resectable Squamous-Cell 
Carcinoma of Esophagus: A 
Phase III Randomized Trial
The study compared the outcomes of surgery plus 
perioperative chemotherapy (PCF: paclitaxel, cisplatin, 
and 5-fluorouracil) with preoperative chemotherapy 
alone in 346 patients with resectable squamous cell 
carcinoma of esophagus. Both arms were randomized 
to 2 preoperative PCF cycles, with 2 additional 
postoperative cycles of PCF given to the perioperative 
arm. The 5-year relapse-free survival and 5-year overall 
survival were significantly improved in the perioperative-
chemotherapy arm versus preoperative-chemotherapy 
arm (hazard ratio [HR] for relapse, 0.62; P < 0.001; HR 
for death, 0.79; P < 0.001). Patients undergone resection 
after chemotherapy achieved a complete response rate of 
24.1% (77 of 320). No increase of PCF-related adverse 
events was observed with the 2 additional postoperative 
PCF cycles. The authors concluded that perioperative 
PCF regimen significantly improved survival outcomes 
of patients with operable esophageal squamous cell 
carcinoma in comparison to preoperative chemotherapy 
alone. (p. 1349)
•	 High-Grade 
Neuroendocrine 
Carcinoma with Bronchial 
Intraepithelial Tumor 
Spread: Possibly a New 
Histologic Feature of Large 
Cell Neuroendocrine 
Carcinoma
A retrospective study of 1778 surgically resected 
lung cancer cases was conducted to evaluate 
bronchial intraepithelial tumor spread in high-grade 
neuroendocrine carcinoma (HGNEC). Histologically 
reviewed HGNECs with bronchial intraepithelial tumor 
spread were examined for neuroendocrine markers, and 
their clinicopathological parameters. Of the 47 HGNEC 
cases, 19.1% (n=9) had bronchial intraepithelial tumor 
spread, in which 8 of them had large cell neuroendocrine 
carcinoma (LCNEC) or small cell lung carcinoma with 
an LCNEC component. Four of these with LCNEC 
component showed continuous tumor spread from the 
primary tumor to the resected end of the bronchus. 
Higher recurrence rate was associated with HGNEC 
showing bronchial intraepithelial tumor spread. 
The findings suggest that bronchial intraepithelial 
tumor spread is common in peripherally located 
HGNEC, particularly those with LCNEC morphology. 
Surgeons and pathologists are urged to be aware of 
this phenomenon, which could also indicate HGNEC 
aggressiveness. (p. 1337)
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RESEARCH WATCH
•	 Clinical Activity of 
Afatinib in Patients with 
Advanced Non-Small-Cell 
Lung Cancer Harboring 
Uncommon EGFR 
Mutations: A Combined 
Post-Hoc Analysis of LUX-
Lung 2, LUX-Lung 3, and 
LUX-Lung 6
other mutations), and group 3 (exon 20 insertions). 
Uncommon EGFR mutations were found in 12% 
patients. Objective responses were observed in 71.1% of 
group 1, 14.3% of group 2 and 8.7% of group 3. Median 
progression-free survival (PFS) and overall survival 
(OS), respectively, were 10.7 months and 19.4 months 
in group 1, 2.9 months and 14.9 months in group 2, and 
2.7 months and 9.2 months in group 3. The analysis 
of the most frequent uncommon mutations revealed 
that objective response was achieved in 77.8% patients 
with Gly719Xaa, 56.3 % with Leu861Gln, and 100% 
with Ser768Ile. Taken together, afatinib demonstrated 
efficacy in non-small cell lung cancer harboring certain 
uncommon EGFR mutations (particularly Gly719Xaa, 
Leu861Gln, and Ser768Ile). Tumors with de-novo 
Thr790Met and exon 20 insertion mutations achieved 
relatively less clinical benefit.
Yang JCH, Sequist LV, Geater SL, et al. Clinical 
activity of afatinib in patients with advanced non-
small-cell lung cancer harbouring uncommon EGFR 
mutations: a combined post-hoc analysis of LUX-
Lung 2, LUX-Lung 3, and LUX-Lung 6. The Lancet 
Oncology 2015;16:830–838.
Single agent, pan-PI3K inhibitor buparlisib (BKM120), 
was being evaluated in this open-label, two-stage, 
phase II study BASALT-1 with Stage 1 treating 63 
patients harboring PI3K pathway-activated, metastatic, 
squamous or nonsquamous NSCLC, who relapsed 
after prior treatments. The squamous and nonsquamous 
groups achieved a 12-week progression-free survival 
rate of 23.3% and 20.0%, respectively. Therefore, both 
groups did not start Stage 2. The analysis of archival 
tissue samples and circulating tumor DNA (ctDNA) 
demonstrated that PI3K pathway mutations could be 
detected in ctDNA but they were more concordant 
with metastatic tissue than with primary biopsies. In 
summary, the study did not meet its Stage 1 primary 
objective. Although PI3K pathway activation was 
detected using ctDNA, it might not be the main 
oncogenic driver in NSCLC. The authors suggested that 
increased efficacy might be observed in combination 
therapies versus monotherapy. (p. 1319)
•	 Safety and Efficacy of 
Buparlisib (BKM120) 
in Patients with PI3K 
Pathway-Activated Non–
Small-Cell Lung Cancer: 
Results from the Phase II 
BASALT-1 Study
B
A
This post-hoc analysis included prospectively collected data from 
tyrosine kinase inhibitor-naïve patients harboring EGFR mutation-
positive stage IIIb-IV lung adenocarcinomas treated with afatinib 
in LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6 (N=600). Patients 
were stratified in the randomized trials by EGFR mutation (exon 
19 deletion [del19], Leu858Arg point mutation in exon 21, or 
other) and ethnic origin (LUX-Lung 3 only; Asian vs. non-Asian). 
All uncommon mutations were categorized into group 1 (point 
mutations or duplications in exons 18–21), group 2 (de-novo 
Thr790Met mutations in exon 20 alone or in combination with 
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versus 29%, and disease control rates were 82% versus 
77%. The overall safety profile of the necitumumab 
regimen was acceptable with no new adverse events. 
The necitumumab arm showed more frequent 
grade ≥3 adverse events (72% vs. 62%), including 
hypomagnesemia and rash, and higher incidence of 
serious adverse events (48% vs. 38%). Treatment 
termination was mostly due to neutropenia and 
thrombocytopenia. The investigators concluded that the 
addition of necitumumab to gemcitabine and cisplatin 
improved OS in the study patient population, indicating 
a new first-line therapeutic strategy for the disease.
Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab 
plus gemcitabine and cisplatin versus gemcitabine and 
cisplatin alone as first-line therapy in patients with stage 
IV squamous non-small-cell lung cancer (SQUIRE): an 
open-label, randomised, controlled phase 3 trial. The 
Lancet Oncology 2015;16:763–774.
This study aimed to estimate the proportion of lung 
cancer cases in Quebec that were “more likely than 
not” caused by cigarette smoking among the patients 
for a class action suit against the tobacco industry. 
The authors measured smoking in terms of pack-years 
to evaluate the dose-response relationship between 
smoking and lung cancer, and the distribution of pack-
years of smoking among cases. The analysis estimated 
that 3 – 11 pack-years satisfy the “more likely than 
not” criterion. More than 90% of lung cancer cases 
in Quebec were found to be legally attributable to 
smoking. The novel methodology used in this study 
would facilitate class action suits against the tobacco 
industry.
Siemiatycki J, Karp I, Sylvestre MP, Pintos J. 
Estimating the proportion of cases of lung cancer legally 
attributable to smoking: a novel approach for class 
actions against the tobacco industry. American J Pub 
Health 2014;104:e60-e66.
•	 Necitumumab Plus 
Gemcitabine and Cisplatin 
versus Gemcitabine and 
Cisplatin Alone as First-
Line Therapy in Patients 
with Stage IV Squamous 
Non-Small-Cell Lung 
Cancer (SQUIRE): An 
Open-Label, Randomized, 
Controlled Phase 3 Trial
•	 Estimating the Proportion 
of Cases of Lung Cancer 
Legally Attributable 
to Smoking: A Novel 
Approach for Class Actions 
Against the Tobacco 
Industry
The phase III study evaluated the treatments with necitumumab plus 
gemcitabine and cisplatin versus gemcitabine and cisplatin alone in 
1093 treatment-naïve patients with stage IV squamous non-small 
cell lung cancer (NSCLC). The necitumumab arm demonstrated 
significantly improved median overall survival (OS) versus the 
control arm (11.5 months vs. 9.9 months; hazard ratio [HR] 0·84; 
P=0·01). Median progression-free survival was 5.7 months versus 
5.5 months (HR 0.85; P=0.02), objective response rates were 31% 
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•	 Attitudes Toward Raising 
the Minimum Age of Sale 
for Tobacco Among U.S. 
Adults
The authors assessed data from an internet survey 
involving 4219 U.S. adults (aged ≥18 years) in order 
to determine attitudes toward increasing the minimum 
tobacco age of sale to 21 years among U.S. adults. 
Participants were asked if they favor or oppose 
increasing the legal minimum age to purchase all 
tobacco products from 18 to 21. The analysis showed 
that 50.4% strongly and 24.6% somewhat favored 
increasing the age to 21 years, in which 77.5% were 
never smokers, 74.6% were former smokers, and 69.9% 
were current smokers. In this group of people who 
favored, the adjusted odds were higher among adults 
aged 25–44 (odds ratio [OR]=1.8), 45–64 (OR=2.3), 
and ≥65 (OR=3.1) years, and were lower among former 
and current smokers (both OR=0.7). In summary, 
adults in favor of increasing the minimum tobacco 
age of sale to 21 years accounted for three quarters of 
the study participants, of which 7 in 10 were smokers. 
Incorporating the increase in minimum age of sale into 
proven tobacco control strategies could help curb youth 
tobacco use.
King BA, Jama AO, Marynak KL, Promoff GR. 
Attitudes Toward Raising the Minimum Age of Sale 
for Tobacco Among U.S. Adults. American Journal of 
Preventive Medicine, doi:http://dx.doi.org/10.1016/j.
amepre.2015.05.012.
NEWS IN BRIEF
•	 BMS Immunotherapy 
Accepted for UK Early 
Access Scheme
The Medicine and Healthcare products Regulatory 
Agency in the UK has granted approval to Bristol-Myers 
Squibb’s immunotherapy Opdivo for Early Access to 
Medicines Scheme (EAMS) for the treatment of patients 
with locally advanced or metastatic squamous non-small 
cell lung cancer, treated with prior chemotherapy. This 
EAMS status would accelerate patient access to the 
treatment in advance of an official green light for its use. 
The approval was based on findings from the Phase III 
CheckMate-017 trial, demonstrating that patients treated 
with Opdivo had a one-year overall survival (OS) rate of 
42% and median OS of 9.2 months compared with 24% 
and 6.0 months, respectively, in the current standard 
care, docetaxel, arm. Opdivo was the first PD-1 inhibitor 
approved in Europe for treating skin cancer.
Image credit: NCI
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NEWS FROM THE 
IASLC TOBACCO 
CONTROL 
COMMITTEE
•	 The TPPA – Countries 
Should Demand a Tobacco 
Carve Out
trade negotiators3 highlighting potential problems with 
domestic labour, the environment, investor-state disputes, 
intellectual property and state-owned enterprises. The 
text is secret, which may explain why it is late to garner 
interest (initial discussions started in 2005 with the “P4” 
Trans Pacific Strategic Economic Partnership between 
Chile, New Zealand, Singapore and Brunei). In late June, 
the Senate (Republican controlled) supported the TPA 
bill 60-38; Congress will as a result be able to accept or 
reject the TPPA (secret until final draft) but not amend 
it or subject it to filibuster4. As far as tobacco control 
goes, there are major concerns about the impact of the 
TPPA, particularly via ISDS provisions. The UK, which 
recently passed plain packaging legislation is facing its 
own lawsuit from Philip Morris International, filed on the 
22nd of May using similar trade agreement arguments as 
those used against Australia5. An interesting and perhaps 
startling perspective for the tobacco control community 
comes from criticism of TPP protestors in a short article 
in The Australian Financial Review6 from July that 
describes the FCTC as “very patchy and unenforceable 
UN convention to regulate tobacco. In legal terms this 
is little more than a code of practice”. After all, we base 
the modern approach to global tobacco control on the 
elements of the FCTC7. We do well to remember the 
contempt in which certain powerful interest groups hold 
the FCTC and all tobacco control efforts. The next and 
potentially last TPPA negotiating session will take place 
28–31 July 2015 in Hawaii.
The Trans-Pacific Partnership Agreement (TPPA) has been 
summarised in previous columns (most recently June 2015) as a new 
type of international trade agreement that is still under negotiation, 
has a number of interested or committed parties and that has the 
potential to affect domestic policy development for the countries that 
are party to it, chiefly via ISDS (investor-state dispute settlement) 
provisions. These provisions allow companies to take legal actions 
against governments, ostensibly to protect them against poor 
decisions. However such provisions in other treaties have been used 
by Big Tobacco to oppose domestic tobacco control policy such as 
the Philip Morris action against Australia’s plain packing legislation1. 
Malaysia which is part of the TPPA has asked other countries to 
endorse a tobacco carve out so tobacco would not be part of any trade 
deals. The Obama Administration hit the TPPA headlines recently 
with a struggle in the US Senate. On the 12th of May, a group of 
Senate Democrats voted to block the Trade Promotion Authority 
bill (the TPA bill not the TPPA)2. This was a “fast-track” bill that 
would give the President authority to negotiate trade agreements, 
which are taking place in secret, much to the frustration of a variety 
of interest groups in the US and around the world. Concerns about 
TPPA secrecy have been published by experienced and senior 
Copyright © 2015 by the International Association for the Study of Lung Cancer
1236 Copyright © 2015 by the International Association for the Study of Lung Cancer
•	 Tobacco Bans and 
e-Cigarettes
e-cigarettes are used by far greater numbers of people 
now than even a short time ago (tripled since 2010)11. 
The largest group by number is the current smoker 
group, where e-cigarettes are used along with tobacco 
cigarettes; the next group is the ex-smoker group and 
the smallest group (about 1%) is the non-smoker group. 
This may mean, drawing upon quotes from anti-smoking 
executives and study leaders, that e-cigarettes are not 
normalising smoking and that they are associated with 
reductions in tobacco cigarette consumption. However 
the director of a smoker support group welcomed 
the presence of e-cigarettes as an extension of choice 
for smokers. For the tobacco control community, 
e-cigarettes promise many more studies, reports and 
discussions on whether they are good or whether they 
are bad. At the moment, the jury is clearly still out.
 1. Seccombe, M. Big Tobacco’s plan to stub out plain pack-
aging. The Saturday Paper (2014). at <https://www.
thesaturdaypaper.com.au/opinion/topic/2014/03/08/
big-tobaccos-plan-stub-out-plain-packaging/1394197200>.
 2. York, J. K. in N. You down with TPP? An explainer 
on Obama’s ‘secret’ trade pact. the Guardian at 
http://www.theguardian.com/us-news/2015/may/12/
trans-pacific-partnership-explainer.
 3. Wessel, M. I’ve Read Obama’s Secret Trade Deal. Elizabeth 
Warren Is Right to Be Concerned. POLITICO Magazine at 
http://www.politico.com/magazine/story/2015/05/tpp-eliza-
beth-warren-labor-118068.html.
 4. Washington, P. L. in. Barack Obama given ‘fast-track’ 
authority over trade deal negotiations. the Guardian 
at http://www.theguardian.com/us-news/2015/jun/24/
barack-obama-fast-track-trade-deal-tpp-senate.
 5. Yaqub, F. Plain packaging for tobacco products faces UK 
legal challenge. Lancet Respir. Med. (2015). doi:10.1016/
S2213-2600(15)00230-1.
 6. PM, O. J. 5 2015 at 3:55 P. U. J. 5 2015 at 7:08. TPP pro-
testers have their own agenda. Financial Review at http://
www.afr.com/opinion/columns/tpp-protesters-have-their- 
own-agenda-20150705-gi5hzl.
 7. WHO | WHO Framework Convention on Tobacco Control. 
WHO at http://www.who.int/fctc/text_download/en/.
 8. Ban on ‘emerging’ tobacco products to kick off from Dec. 
TODAYonline at http://www.todayonline.com/singapore/
ban-emerging-tobacco-products-kick-dec.
 9. Wales to usher in e-cigarette ban in public spaces. The 
Week UK at http://www.theweek.co.uk/58735/e-cigarettes-
become-the-alcopops-of-the-nicotine-world.
 10. Shabad, R. Spending bill exempts e-cigs from FDA review. 
TheHill (2015). at http://thehill.com/policy/finance/247214-
gop-rejects-proposal-to-allow-fda-to-regulate-e-cigarettes.
 11. E-cigarette users in UK have ‘tripled’ since 2010. BBC News 
at http://www.bbc.com/news/health-27161965.
Singapore is setting a standard in bans of tobacco and related 
products, including any products that contain nicotine. In a report 
from Today8, the Singapore government will introduce from 
December 2015 a ban on emerging smokeless tobacco products not 
already in the market such as smokeless cigarettes and cigars as 
well as topical, implant or injectable products containing tobacco 
or nicotine and e-cigarettes. From August 1 2016, the ban will also 
include emerging tobacco products already in the market including 
various forms of snuff and chewable tobacco. Products registered 
under the Medicines Act are excluded from the ban. E-cigarette 
news is always puzzling to report on. Over the last month alone 
we have a multitude of conflicting commentaries, attitudes and 
policies presented in the media. From Wales, The Week reports 
on planned legislation to ban the use of e-cigarettes in public 
places, supported by Public Health Wales and the British Medical 
Association, but opposed by respected organisations such as ASH 
Wales (an anti-smoking group) and Cancer Research UK9. In the 
United States, The Hill carries the headline “Spending bill exempts 
e-cigs from FDA review”10. This slightly confusing article does a 
stunning turn in serial negatives in its first sentence – an amendment 
is blocked…a provision is removed….to make exempt….. and so 
on (….till the house that Jack built…). What the article actually 
says, I think, by the end is that a bill to fund the FDA to regulate 
e-cigarettes (among other things) was threatened by a provision that 
would have made e-cigarettes exempt from the FDA pre-market 
review process. An amendment was proffered by a Democrat 
representative and was blocked by Republicans. This means that 
a handbrake on the introduction of e-cigarettes to the market may 
not come into being. But it is a little hard to be sure. And not even 
the BBC, that perennial voice of reason and reassurance, can tell 
us whether e-cigarettes are good or bad. BBC News reports that 
Image credit: FDA
